Cargando…
Redefining the role of thiazolidinediones in the management of type 2 diabetes
There is a need to evaluate oral glucose-lowering agents not only for their value in achieving glycemic control but also for their impact on cardiac risk factor modification. This article reviews the evidence base for the two thiazolinediones currently available, pioglitazone and rosiglitazone. Thes...
Autor principal: | Barnett, Anthony H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672454/ https://www.ncbi.nlm.nih.gov/pubmed/19436665 |
Ejemplares similares
-
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021) -
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022) -
Type 2 Diabetes: Uses of thiazolidinediones and insulin
por: T. Bloomgarden, Zachary
Publicado: (2011) -
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
por: Stafford, John M, et al.
Publicado: (2007) -
A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications
por: Behzad, Molavi, et al.
Publicado: (2007)